HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

• Published in: BMC cancer Vol. 22; no. 1; pp. 1081 - 10
• Main Authors: Cherifi, François, Da Silva, Angélique, Johnson, Alison, Blanc-Fournier, Cécile, Abramovici, Olivia, Broyelle, Antonin, Levy, Christelle, Allouache, Djelila, Hrab, Ioana, Segura, Carine, Morel, Adeline, Villemin, Maud, Boscher, Clémence, Dubot-Poitelon, Coraline, Rottier, Pauline, Lequesne, Justine, Emile, George
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.10.2022; BioMed Central; BMC
• Subjects: Adjuvant treatment; Analysis; Antibody-drug conjugates; Antimitotic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Diagnosis; Disease-Free Survival; Dosage and administration; Embolisms; ErbB-2 protein; Female; Gene amplification; HER2-low; Hormones - therapeutic use; Humans; Hybridization; Immunohistochemistry; Leukocytes (neutrophilic); Lymphatic system; Lymphocytes; Medical prognosis; Middle Aged; Monoclonal antibodies; Neoadjuvant Therapy; Neoadjuvant treatment; Neutrophils; Patients; Prognosis; Receptor, ErbB-2 - metabolism; Retrospective Studies; Surgery; Targeted cancer therapy; Trastuzumab–deruxtecan; Tumors; France; HER2-low; Antibody–drug conjugates; Lymphocytes; Neutrophils; Breast cancer; Trastuzumab–deruxtecan; Neoadjuvant treatment
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10163-9

HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted therapies. The concept of HER2-low BC (IHC score 1 + or 2 + without ISH amplification) is drawing attention as anti-HER2 treatment has recently shown efficacy in this subgroup. We aimed to explore the response to neoadjuvant chemotherapy (NAC) in HER2-low early BC according to the HER2 score (1 + or 2 + without amplification). We conducted a retrospective study in two French comprehensive cancer centers. All patients with HER2-low BC treated with NAC from January 2014 to December 2020 were included. The primary objective was to analyze the pathological complete response (pCR) rate to NAC using the Sataloff or RCB system, according to the HER2 score. Secondary objectives were to assess disease free survival (DFS), overall survival (OS) and to explore the immune environment through the Neutrophil-to-Lymphocyte Ratio (NLR), according to HER2 expression. Univariate and multivariate analyses were performed. We included 237 tumors for 229 patients. Of these, 160 (67.5%) tumors were HER2 1 + , 77 (32.5%) were HER2 2 + , and 152 (64.1%) were hormone receptor (HR) positive. The median age was 53.9 years. No differences in tumor characteristics were observed between HER2 1 + and HER2 2 + subgroups. pCR was achieved in 38 tumors (17%), without any difference between HER2 1 + and HER2 2 + subgroups (p = 0.77). DFS and OS were significantly different between HER2 1 + and HER2 2 + patients (HR = 0.41,CI95%[0.17;0.97] p = 0.037 and HR = 0.31,CI95%[0.09;1.02] p = 0.042, respectively). HER2 status was still associated with DFS and OS after adjustment for age, HR status and NLR, with better outcomes in favor of HER2 score 2 + (HR = 0.35 [0.15-0.84] and HR = 0.24 [0.07-0.81], respectively). NLR was not associated with worse DFS or OS. In HER2-low early BC, no differences in pCR were observed between HER2 1 + and HER2 2 + tumors, however patients with HER2 2 + tumors had a better DFS and OS than those with HER2 1 + . Further investigations are needed to describe the intrinsic differences in the spectrum of HER2-low BC.